Overview

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Deferoxamine